<!doctype html>
 <html>
 <head>
 <meta charset='UTF-8'>
 <title>Bio</title>
 <style type='text/css'>
 	.in-bio-photo{
     width: 200px;
     height: 200px;
     border-radius: 100%;
     text-align: center;
 }	
 </style>
 </head>
  <body>
 <p style='text-align: center'><img class='in-bio-photo' src='/dtm/bios/2022/basu.jpg' alt='speaker-headshot'/></p><p style='text-align: center; font-weight: bold;'>Ananda Basu, MD, FRCP<br/>University of Virginia, Charlottesville , Virginia</p><p>
 Dr. Ananda Basu, MBBS, MD, FRCP, is a Harrison Distinguished Professor of Medicine at the University of Virginia School of Medicine. His area of interest is integrated carbohydrate physiology and hormonal regulation of carbohydrate metabolism in type 1 and type 2 diabetes. He has worked in this field at Mayo Clinic, Rochester, MN since 1993 and continues to do so at the University of Virginia since he moved in 2017. In the last 25 years of independent federal funding, he has helped develop and applied state of the art research tools involving innovative isotope dilution methods to enhance our understanding of carbohydrate physiology in </span><span style="font-style:italic;" >type 1 diabetes </span>with the ultimate goal to inform, refine and help develop the next generation of artificial endocrine pancreas (AP) that re-creates, to the extent possible a truly artificial islet The triple tracer method that he helped develop, is currently the gold standard for in vivo assessment of postprandial carbohydrate turnover and &beta; cell functions and forms the underpinnings of the FDA endorsed Type 1 diabetes simulator. Glucagon kinetics, &alpha; cell physiology and intra-islet network (&beta;-&alpha; cell interplay) is insufficiently investigated in humans, especially in those with type 1 diabetes. In order to refine the next generation multi-hormonal closed loop control algorithms to restore normal insulin-glucagon hormonal milieu he has developed an innovative isotope dilution technique using stable-labeled glucagon isotope to measure parameters of glucagon kinetics in humans directly and in vivo. </p><p>He is particularly interested in the translational aspects of implementing diabetes technology in the outpatient clinic and is the Founder-Director of the Diabetes Technology Clinic at UVA that follows close to 1000 patients with Type 1 diabetes in the community. Dr. Basu attended medical school in India, trained in endocrinology in the UK before completing residency and fellowship training in Endocrinology at Mayo Clinic in Rochester, MN and joined the faculty there in 2000, before his move to UVA in 2017. </p>
 </body>
 </html>